Grove Biopharma is a preclinical biotechnology startup, pioneering the discovery and development of a new class of synthetic biologic drug modality to access challenging drug targets. Our Protein-Like-Polymer therapeutic platform has the potential to address significant unmet medical needs in oncology, neurodegenerative disease, and other rare diseases.
Employees: 1-10
Total raised: $30M
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | Deepwork C... | deepworkca... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.04.2025 | Series A | $30M | - |
Mentions in press and media 9
| Date | Title | Description |
| 15.08.2025 | Grove Biopharma to Participate in Materials Biology Symposium at ACS Fall 2025 Scientific Meeting | – Co-Founder, President and CTO Paul Bertin, Ph.D., and Scientific Founder Nathan Gianneschi, Ph.D., to Present Progress with Company’s Bionic Biologics™ Platform – CHICAGO–(BUSINESS WIRE)–August 15, 2025– Grove Biopharma, a private biotech... |
| 27.04.2025 | Grove Biopharma: $30 Million Series A Secured For Advancing Therapeutic Modality | Grove Biopharma is a private biotechnology company advancing its Bionic Biologics platform, developing therapies targeting previously intractable intracellular disease targets. The company has announced the closing of a $30 million Series A... |
| 25.04.2025 | Grove Biopharma: Pioneering a New Era in Therapeutics with $30 Million Series A Financing | In the bustling world of biotechnology, innovation is the lifeblood that fuels progress. Grove Biopharma, a Chicago-based company, has recently secured $30 million in Series A financing, a significant leap towards revolutionizing drug devel... |
| 24.04.2025 | Grove Biopharma Raises $30M in Series A Financing | Grove Biopharma, a Chicago, IL-based biotechnology company, raised $30M in Series A funding. The round was led by DCVC Bio with participation from Eli Lilly and Company, InVivium Capital, Walder Ventures, Gradiant Corporation, Mansueto Inve... |
| 23.04.2025 | Grove Biopharma Closes $30 Million Series A Financing to Advance Bionic Biologics™, a New Therapeutic Modality | – Proprietary Platform Integrates Principles of Biologic and Synthetic Design, Producing Drug Candidates that Selectively Disrupt or Degrade Previously Intractable Intracellular Targets – – Experienced, Multidisciplinary Team Well-Positione... |
| 10.05.2021 | Grove Biopharma Launches with a Novel Biotherapeutic Modality Platform; Portal Innovations Leads Oversubscribed Seed-Stage Investment | Professor Gianneschi’s protein-like polymer (PLP) platform is a revolutionary innovation at the interface between materials engineering, biology, chemistry, and data science with the potential to address important biological disease targets... |
| 10.05.2021 | Grove Biopharma Launches with $4M Seed Round | CHICAGO, IL, Grove Biopharma has successfully closed an oversubscribed $4 million seed round. >> Click here for more funding data on Grove Biopharma >> To export Grove Biopharma funding data to PDF and Excel, click here P... |
| - | Grove Biopharma | “Grove Biopharma – Pioneering Proteomimetic Therapeutics” |
| - | Grove Biopharma | “Grove is pioneering Bionic Biologics, a breakthrough synthetic drug modality that can penetrate cells and reach protein-protein interactions that drive disease.” |